What Kiss Peptide is
Kiss Peptide is a casebook on two peptides studied in the context of sexual and reproductive biology: kisspeptin and PT-141 (bremelanotide). It works to make a specialized and often overstated literature legible — telling a reader, in plain language and with citations, what each compound was actually studied for, in which populations, and how far that evidence reaches.
The organizing frame is the reproductive hormone axis and the neuroscience of sexual desire — two systems that are related but distinct. Kisspeptin acts upstream on the endocrine axis that produces sex hormones. PT-141 acts centrally on the brain circuits that generate the experience of desire. Reading them together gives a more complete picture of how the reproductive and sexual systems can be studied from different entry points. Each compound has its own page, a comparison page lines them up side by side, and a single shared references list aggregates every source across the site.
How it is compiled
What lands on these pages is governed by a few commitments. Every research claim is anchored to the peer-reviewed literature — PubMed-indexed journals, FDA regulatory documents, and systematic reviews, each numbered and collected on the references page; where a finding rests on a review rather than a primary study, the review is cited as such.
Evidence is reported at its true strength. Doses and outcomes stay in the population and context they were studied in — "3.2 nmol/kg subcutaneously in IVF patients at high OHSS risk," for instance — and are never translated into human recommendations. Where an approval is narrow (PT-141's single indication), that narrowness is stated up front, not softened; where the evidence reaches only Phase 1 and Phase 2 (kisspeptin), that stage is the headline, not a footnote.
The cautions travel with the benefits. Tachyphylaxis in kisspeptin, nausea and blood-pressure effects in PT-141, the limits of what research-grade material actually is — these are drawn from the same literature that documents the upside, and they carry the same weight rather than being appended as an afterthought.
What it is not
Kiss Peptide sells nothing, treats no one, and offers no medical advice. It does not supply, source, or broker any peptide or research chemical, and it holds no affiliate or referral tie to any vendor. No clinician staffs it; it diagnoses no condition and prescribes nothing, and it recommends no dose, schedule, or route for any person.
The peptides here carry regulatory statuses that matter: kisspeptin is investigational, with no approved form anywhere; PT-141 (bremelanotide) is FDA-approved only for premenopausal women with HSDD, and material sold as "PT-141 research chemical" is not the approved pharmaceutical. The summaries on this site do not change those facts, and they are not a basis for self-administration. Readers interested in any condition described in the underlying research should consult a licensed clinician operating within their own jurisdiction.